Who we are

Our Story


The vision of our shareholders, hand in hand with the talent of our team, allows the Stendhal story to continue to be built to meet our motto: Caring for Life.

2023

Leadership in Orphan Drugs

The company is established as a leader in orphan drug therapies.

2021

Rare Diseases

Stendhal signs licenses with 10 business partners, adding therapies for the care of rare diseases to its portfolio.

2020

Supportive Therapy

The drug Methoxyflurane is included to contribute to the effective and safe treatment of patients with acute, moderate, or severe pain.

2019

Primary Care Product Expansion

Stendhal makes a strategic alliance to expand the distribution and marketing of primary care products in Mexico, Central America, and the Caribbean.

Remodelación de Planta Stendhal

Create independence of access to the microbiology laboratory ID: MB-LAB-04 from the general corridor ID:PO-FB-15, creation of a new warehouse and relocation of raw material storage, relocation of the sampling area and the sample area retention, creation of a transfer for the exit of RPBI waste from the microbiology laboratory ID: MB-LAB-04.

2017

Central Nervous System and Oncology

Stendhal’s product portfolio continues to grow with the inclusion of Dimethyl Fumarate, the first oral treatment for multiple sclerosis. Also, incursions into molecules for advanced oncology therapies are initiated.

2015

Consolidation

Stendhal is established across various national rankings as one of the most important companies in Mexico. The company is positioned as one of the Top 500 Mexican Companies.

2013

Cardiovascular Portfolio

Commercial agreements are initiated to include innovative molecules for the cardiovascular area in the portfolio. The Cardiovascular Business Unit is formed and a molecule for arterial hypertension is launched. Stendhal becomes the first North American partner of Korea's pharma industry.

2012

Stendhal Territory Expansion

Operations begin in the Dominican Republic; Stendhal now operates in 14 countries.

2010

Leader in Innovative Therapies

Stendhal is established as an undisputed leader in the treatment of HIV/AIDS and multiple sclerosis, with innovative treatments for critical care and genetic disorders. The product portfolio is strengthened by incorporating the first comprehensive treatment for HIV/AIDS in Mexico in the form of a tablet.

2009

Stendhal Americas

Stendhal partners with Eicopen Pharma, expanding its presence in Central America and the Andean Zone.

2008

Neurology and Neuroscience

Stendhal ventures into Neurology by launching the first monoclonal antibody for the treatment of multiple sclerosis, leading to the creation of the Neurosciences Business Unit.

2007

Leadership in HIV/AIDS

Stendhal becomes a leader in HIV/AIDS treatments.

2005

Creation of the Oncology Business Unit

Creation of the Oncology Business Unit in a business alliance with Baxter.

2004

Creation of the HIV Business Unit

Launch of the first line of products for the treatment of HIV/AIDS, which gives rise to the formation of the HIV Business Unit.

2003

Major Changes

Signing of the first commercial agreement with Gilead Sciences Inc. for anti-infective products. The remodeling of the manufacturing site is carried out, achieving high world-class standards in good practices for manufacturing, conditioning and storage, and product distribution and control.

Stendhal Facilities

The remodeling of the pharmaceutical plant in the State of Mexico begins. Stendhal's philosophy is developed as a company dedicated to innovative and high-tech medicine for critical conditions that put human life at risk.

1997

Acquisition

A group of Mexican investors acquires Stendhal. A comprehensive transformation occurs by renewing the philosophy and business mission that shaped the company.

1996

Stendhal Facilities

Expanding the business vision, Stendhal Plant was acquired, a pharmaceutical laboratory founded in 1974. To give strength to this new organization, measures are implemented to optimize internal processes.

1974

Stendhal is Born

Stendhal is born as a Pharmaceutical Laboratory.

Logo Stendhal

Tel. +(52) 55 2000 66 30
Address: Camino a Santa Teresa No. 1040, Mezzanine 1, Col. Jardines en la Montaña,
Alcaldía Tlalpan, C.P. 14210, Ciudad de México, México

© Stendhal International 2024. All Rights Reserved. Stendhal Pharma is owned by Específicos Stendhal, S.A. de C.V.